Yutaka Matsuda
Yutaka Matsuda publishes mostly in Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology, on topics such as Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research and Protein purification and stability.
- World rank
- #1,121,056 of 7,710,434 ranked researchers
- Rank in Japan
- #15,822 of 383,136
- Works
- 152
- Citations
- 2.1k
- Citations per work
- 13.6
What does Yutaka Matsuda research?
Yutaka Matsuda's work is mostly in Medicine (36%), Biochemistry, Genetics and Molecular Biology (26%), Chemistry (9%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences5535.9%
- Medicine5535.9%
- Life Sciences3925.7%
- Everything else3623.4%
- Physical Sciences2315.0%
- Chemistry149.4%
- Engineering95.6%
- 1Molecular Biology24% of their works
- 2Radiology, Nuclear Medicine and Imaging18% of their works
- 3Oncology18% of their works
- 4Organic Chemistry9% of their works
- 5Biomedical Engineering6% of their works
- 6Biotechnology2% of their works
Research topics
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Protein purification and stability
- Click Chemistry and Applications
- Chemical Synthesis and Analysis
- Nanofabrication and Lithography Techniques
- Viral Infectious Diseases and Gene Expression in Insects
- Peptidase Inhibition and Analysis
Which keywords describe Yutaka Matsuda's research?
The keywords of their largest research topics: Monoclonal Antibodies, Therapeutic Antibodies, Glycosylation, Antibody Engineering, Fc Receptors, Monoclonal Antibody, Breast Cancer and HER2.
- Recombinant Protein
- Fibroblast Activation Protein
- Nanolithography
- Foldamers
- Copper-Catalyzed Cycloaddition
- Biopharmaceuticals
- HER2
- Monoclonal Antibody
- Antibody Engineering
- Therapeutic Antibodies
- Monoclonal Antibodies
- Glycosylation
- Fc Receptors
- Breast Cancer
- Drug Discovery
- Click Chemistry
- Protein Aggregation
- Peptide Synthesis
- Soft Lithography
- Mammalian Cells
- Tumor Microenvironment
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Monoclonal Antibodies622 topics
- Therapeutic Antibodies622 topics
- Glycosylation562 topics
- Antibody Engineering491 topic
- Fc Receptors491 topic
- Monoclonal Antibody432 topics
- Breast Cancer361 topic
- HER2361 topic
- Drug Discovery222 topics
- Biopharmaceuticals131 topic
- Click Chemistry131 topic
- Copper-Catalyzed Cycloaddition131 topic
- Protein Aggregation131 topic
- Foldamers91 topic
- Peptide Synthesis91 topic
- Nanolithography81 topic
- Soft Lithography81 topic
- Fibroblast Activation Protein71 topic
- Mammalian Cells71 topic
- Recombinant Protein71 topic
- Tumor Microenvironment71 topic
Where does Yutaka Matsuda work?
Yutaka Matsuda's main affiliation in the publication record is Ajinomoto (Japan), Japan.
How many publications and citations does Yutaka Matsuda have?
OpenAlex counts 152 works and 2,071 citations for Yutaka Matsuda, an h-index of 28, ranking #1,121,056 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Yutaka Matsuda. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.